Salivary Fusobacterium nucleatum serves as a potential diagnostic biomarker for gastric cancer

Table 2 Characteristics and levels of biomarkers among different subjects

	Normal control	Atrophic gastritis	Non-atrophic gastritis	Gastric polyps	Gastric cancer
Cases	20	31	35	26	120
Gender (male/female)	13/7	17/14	19/16	15/11	73/47
Age (yr)1	56.90 ± 16.02	62.13 ± 10.56	60.80 ± 14.54	58.17 ± 15.26	61.38 ± 10.31
CEA (mg/L)2,3	2.03 (1.22-2.56)	1.95 (1.49-53.37)	1.72 (1.44-2.60)	1.36 (1.10-1.85)	2.46 (1.38-4.63)
CA19-9 (pg/mL)2,3	6.38 (3.61-11.39)	10.67 (8.68-16.35)	10.30 (7.09-15.07)	9.20 (5.68-12.09)	11.46 (6.75-20.28)
CA72-4 (U/mL)2,3	2.86 (0.98-6.48)	0 (0-3.18)	2.41 (1.50-4.65)	1.71 (0.15-4.63)	2.58 (0-5.69)
Ferritin (ng/mL)2,3	143.15 (97.04-273.98)	96.98 (69.33-206.55)	126.70 (74.49-245.30)	182.95 (101.13-263.88)	86.20 (25.99-165.75)
Sialic acid (g/L)2,4	54.30 (51.45-56.75)	52.50 (46.50-55.30)	53.70 (48.25-60.55)	56.2 (50.53-59.65)	59.55 (53.28-65.33)
Fusobacterium nucleatum (copies/μL)2,4	16.70 (2.4-26.10)	28.611 (5.99-61.50)	12.18 (0.74-35.55)	16.32 (1.59-122.234)	177.09 (53.09-547.11)

¹Data are presented as the mean ± SD.

²Data are presented as the median (interquartile range).

³Date are compared using Kruskal-Wallis test, P < 0.05.

⁴Date are compared using Kruskal-Wallis test, P < 0.001.

CEA: Carcinoembryonic antigen; CA19-9: Carbohydrate antigen 19-9; CA72-4: Carbohydrate antigen 72-4.